Ikarian Capital’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,456,378
| Closed | -$76.8M | – | 192 |
|
|
2026
Q1 | $76.8M | Sell |
1,456,378
-140,000
| -9% | -$5.75M | 6.23% | 2 |
|
|
2025
Q4 | $64.5M | Buy |
1,596,378
+1,432,176
| +872% | +$33.1M | 5.04% | 4 |
|
|
2025
Q3 | $1.23M | Buy |
164,202
+105,711
| +181% | +$675K | 0.12% | 116 |
|
|
2025
Q2 | $218K | Sell |
58,491
-250,000
| -81% | -$781K | 0.04% | 111 |
|
|
2025
Q1 | $851K | Hold |
308,491
| – | – | 0.1% | 100 |
|
|
2024
Q4 | $1.71M | Sell |
308,491
-6
| -0% | -$41 | 0.23% | 86 |
|
|
2024
Q3 | $2.57M | Sell |
308,497
-150,000
| -33% | -$1.23M | 0.36% | 68 |
|
|
2024
Q2 | $3.12M | Buy |
458,497
+370,000
| +418% | +$2.24M | 0.54% | 45 |
|
|
2024
Q1 | $581K | Sell |
88,497
-76,983
| -47% | -$503K | 0.06% | 116 |
|
|
2023
Q4 | $1.07M | Hold |
165,480
| – | – | 0.1% | 98 |
|
|
2023
Q3 | $832K | Sell |
165,480
-150,000
| -48% | -$952K | 0.1% | 101 |
|
|
2023
Q2 | $2.76M | Sell |
315,480
-405,861
| -56% | -$4.73M | 0.44% | 54 |
|
|
2023
Q1 | $8.54M | Sell |
721,341
-15,978
| -2% | -$153K | 1.94% | 14 |
|
|
2022
Q4 | $7.51M | Sell |
737,319
-166,800
| -18% | -$1.11M | 1.81% | 18 |
|
|
2022
Q3 | $5.33M | Buy |
904,119
+204,119
| +29% | +$758K | 1.06% | 33 |
|
|
2022
Q2 | $1.74M | Buy |
+700,000
| New | +$1.4M | 0.32% | 64 |
|
Other funds holding TERN
Ikarian Capital's TERN Position: Q2 2026 in Review
Ikarian Capital sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 1,456,378 shares — an estimated $76.8M sold.
Ikarian Capital first reported a position in TERN in Q2 2022 and held it in 16 quarters. The position peaked at $76.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Ikarian Capital reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Ikarian Capital sold 1,456,378 Terns Pharmaceuticals shares in Q2 2026, an estimated $76.8M.
- Ikarian Capital first reported a position in Terns Pharmaceuticals in Q2 2022 and held it in 16 quarters.
- Ikarian Capital's Terns Pharmaceuticals position peaked at $76.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.